Reducing HIV Stigma for African American Women

Completed · Not applicable

Conditions studied: HIV

In brief

African American women account for 66% of HIV infections in women in the U.S., AIDS is a leading cause of death for African American women, and African Americans have the lowest medication adherence rates compared to other groups in the U.S. One of the reasons for low medication adherence among African Americans is fear of stigma. HIV stigma has been linked to depression, psychological distress, poor quality of life, poor medication adherence and service utilization contributing to morbidity and mortality. Research has found that stigma is a moderator to poor adherence via depressive symptoms. The current study is a randomized control trial with a time and attention control group to test the effectiveness of a stigma reduction intervention adapted for use with African American women. A total of 224 African American women will be recruited to participate in the study. Half of the women will be from Chicago, Illinois (112) and the other half will be from Birmingham, Alabama (112). A workshop will be held once a study site has recruited 28 women, half of the women will be in the intervention group (14) and the other half will be in the control group (14). Each study site will have 4 cohorts of 28 women. The main aims of the current study are: 1. to determine the long-term effectiveness of the intervention to reduce stigma for African American women living with HIV in Chicago Illinois and Birmingham, Alabama 2. to examine whether stigma reduction due to the intervention is associated with improved physical health biomarkers (CD4+ T cell count, viral load), mediated by reduced psychological symptoms (depressive symptoms), improved engagement to care, and improved medication adherence 3. to explore whether stigma reduction due to the intervention is moderated by location (Chicago vs. Birmingham), transmission risk factor, time since diagnosis, and perceived social support We expect that the multimedia workshop intervention will demonstrate effectiveness in reducing internalized stigma through an easily-disseminated method, and that it will have a positive impact on medication adherence and engagement in care for African American women living with HIV.

Key facts

Study ID

NCT01893112

Run by

University of Washington

People needed

240

Starts

2013-06-01

Expected to finish

2017-02-01

Last updated by the study team

2017-05-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• they are women who identify as having an African American racial/ethnic background
• born in the U.S. (including women of Caribbean origin if born in the U.S.
• speak and understand English as their primary language of communication outside the home
• they are 18 years of age or older
• have a documented HIV positive status (women are on antiretroviral treatment and women who are not on antiretroviral are eligible)
• able to see and interact with a touchscreen computer in English.

You may not qualify if…

• women who not self-identify as African American
• women who are African born or born outside the United States
• younger than 18 years of age
• unable to provide informed consent
• life expectancy less than 1 year per physician report
• unable to see and interact with a touchscreen computer in English.

Where it is running

• University of Alabama Birmingham — Birmingham, Alabama, United States
• Northwestern University (NU) — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.